Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists (Q36171870)

12 August 2017

0 references

Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists (English)

1 reference

12 August 2017

0 references

Isidoro González-Alvaro

1

1 reference

12 August 2017

Ana M Ortiz

2

1 reference

12 August 2017

Eva G Tomero

3

1 reference

12 August 2017

Alejandro Balsa

4

1 reference

12 August 2017

Javier Orte

5

1 reference

12 August 2017

Armando Laffon

6

1 reference

12 August 2017

Rosario García-Vicuña

7

1 reference

12 August 2017

language of work or name

English

0 references

publication date

31 July 2007

1 reference

Annals of the Rheumatic Diseases

12 August 2017

1 reference

12 August 2017

66

1 reference

12 August 2017

12

1 reference

12 August 2017

1675-1678

1 reference

Osteoclasts, rheumatoid arthritis, and osteoimmunology

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

Serum levels of osteoprotegerin increase with age in a healthy adult population

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

Correlates of osteoprotegerin levels in women and men.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095335

High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment

21 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17666448

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17666448

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/ARD.2007.071910

1 reference

12 August 2017

1 reference

12 August 2017

1 reference